REG - hVIVO PLC - Broker change

hVIVOAnnouncement

08/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240108:nRSH8647Ya&default-theme=true

RNS Number : 8647Y  hVIVO PLC  08 January 2024

hVIVO plc

("hVIVO" or the "Company")

 

Appointment of Nominated Adviser and Joint Broker

 

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious
and respiratory disease products using human challenge clinical trials,
announces the appointment of Cavendish Capital Markets Limited as Nominated
Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate
effect.

 

For further information please contact:

 

 hVIVO plc                                           +44 (0) 20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)        +44 (0) 20 7220 0500
 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward

 Peel Hunt LLP (Joint Broker)                                                  +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Euronext Growth Adviser and Joint Broker)                               +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                     +44 (0) 20 7933 8780 or hvivo@walbrookpr.com

 Stephanie Cuthbert / Phillip Marriage /             +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /

Louis Ashe-Jepson
+44 (0) 7747 515 393

 

Notes to Editors

 

About hVIVO

 

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing
specialist contract research organisation (CRO) and the world leader in
testing infectious and respiratory disease vaccines and therapeutics using
human challenge clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat client base,
which includes four of the top 10 largest global biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 11
human challenge models, with a number of new models under development, to test
a broad range of infectious and respiratory disease products. The Company has
world class challenge agent manufacturing, specialist drug development and
clinical consultancy services via its Venn Life Sciences brand, and a lab
offering via its hLAB brand, which includes virology, immunology biomarker and
molecular testing. The Group offers additional clinical field trial services
such as patient recruitment and clinical trial site services.

 

hVIVO runs challenge studies in London from its Whitechapel quarantine
clinic, its state-of-the-art QMB clinic with its highly specialised on-site
virology and immunology laboratory, and its clinic in Plumbers Row. To recruit
volunteers / patients for its studies, the Company leverages its unique
clinical trial recruitment capability via its FluCamp
(https://eur05.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.flucamp.com%2F&data=05%7C01%7CCarol.Dalton%40openorphan.com%7Cfb9f1a50aaa9492d81ed08da875cca71%7C131abc777e104bbd90170559abc5d601%7C1%7C0%7C637971129881295595%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=fQdtQTHu9Bo70yRgWcZW5liNTXPYiWl9YayUA01E%2FlA%3D&reserved=0)
 volunteer screening facilities in London and Manchester.

 

Existing Board - AIM Rule 17 Disclosure

 

The Company announces the following additional director disclosures pursuant
to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

 

Elaine Sullivan

 

In addition to the disclosures made in Elaine Sullivan's announcement of
appointment on 24 November 2020, the following directorships are disclosed:

 

 Company                       Current, or last 5 years
 Carrick Therapeutics Limited  Directorship held in last 5 years, at time of appointment to hVIVO

 

Brendan Buckley

 

The following directorships were disclosed incorrectly in the Company's
Admission Document dated 9 December 2019:

 

 Company                                                                   Disclosure
 Irish Platform for Patients' Organisations, Science and Industry Company  Directorship held more than 5 years prior to publication of the Admission
 Limited                                                                   Document and therefore should not have been disclosed in the Admission
                                                                           Document

 

 

Cathal Friel

 

In addition to the disclosures made in the Admission Document dated 9 December
2019, the following directorships are disclosed:

 

 Company                                       Current, or last 5 years
 Amryt Pharma Holdings Limited                 Directorship held in last 5 years at time of Admission Document publication

 Venn Life Sciences Limited                    Current directorship at the time of Admission Document publication

 Venn Life Sciences (Germany) GmbH

 Venn Life Sciences (Ireland) Limited

 Venn Life Sciences (NI) Limited

 Venn Life Sciences (Australia) Pty Ltd

 Venn Life Sciences Inc.

 Venn Life Sciences Legal Representation B.V

 Venn Life Sciences ED B.V.

 Venn Life Sciences (France) SAS

 Venn Life Sciences B.V.

 

The following directorships were disclosed incorrectly in the Company's
Admission Document dated 9 December 2019:

 

 Company                            Current, or last 5 years
 Amryt Pharma plc                   Incorrectly disclosed as a directorship
 Fastnet Hydrocarbons Limited       Directorship held in last 5 years at time of Admission Document publication.

                                  These directorships were disclosed as current directorships in the Admission
 Raglan Natural Resources Limited   Document

 Fitzwilliam Place Capital Limited  Directorship held more than 5 years prior to Admission Document publication
                                    and therefore should not have been disclosed in the Admission Document

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPQKABQBBKDCDK